Literature DB >> 12297606

Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C.

Robert J Fontana1, Steven M Schwartz, Achamyeleh Gebremariam, Anna S F Lok, Cheryl A Moyer.   

Abstract

The aim of the study was to describe the use of the Brief Symptom Inventory in characterizing the type and severity of emotional distress in 26 patients with chronic hepatitis C who were receiving interferon-alpha-2B and ribavirin. The 6-month actuarial incidence of neuropsychiatric toxicity, determined by physician interview, was 58%. Significant differences in mean depression, anxiety, and somatization Brief Symptom Inventory T scores were noted in the 15 patients with clinically apparent neuropsychiatric toxicity compared to the 11 patients without neuropsychiatric toxicity. Because of its brevity and simplicity, the Brief Symptom Inventory may prove to be a useful adjunct to clinician assessment in detecting and monitoring emotional distress during interferon-alpha treatment of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297606     DOI: 10.1176/appi.psy.43.5.378

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  11 in total

Review 1.  Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders.

Authors:  George M Slavich; Julia Sacher
Journal:  Psychopharmacology (Berl)       Date:  2019-07-29       Impact factor: 4.530

2.  Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.

Authors:  Debika Bhattacharya; T Umbleja; F Carrat; R T Chung; M G Peters; F Torriani; J Andersen; J S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

3.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

4.  Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C.

Authors:  Shehab M Abd El-Kader; Osama H Al-Jiffri; Fadwa M Al-Shreef
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

Review 5.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

Authors:  Kimberley J Smith; Suzanne Norris; Cliona O'Farrelly; Shane M O'Mara
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

7.  Major depression during interferon-alpha treatment: vulnerability and prevention.

Authors:  Francis E Lotrich
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

8.  Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.

Authors:  Alain H Litwin; Karina M Berg; Xuan Li; Jennifer Hidalgo; Julia H Arnsten
Journal:  BMC Infect Dis       Date:  2011-11-12       Impact factor: 3.090

9.  Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C).

Authors:  Aybike Birerdinc; Arian Afendy; Maria Stepanova; Issah Younossi; Ancha Baranova; Zobair M Younossi
Journal:  Brain Behav       Date:  2012-07-06       Impact factor: 2.708

10.  Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy.

Authors:  Mauro G Carta; Maria Carolina Hardoy; Alessandra Garofalo; Enrica Pisano; Valentina Nonnoi; Gesuina Intilla; Giancarlo Serra; Cinzia Balestrieri; Luchino Chessa; Cristiana Cauli; Maria Eliana Lai; Patrizia Farci
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.